Form 4: enGene Holdings Inc. Executive Raj Som Pruthi Granted Stock Options

Chief Medical Officer Raj Som Pruthi received stock options for 110,000 common shares in enGene Holdings Inc. on July 24, 2024.

Summary

• Raj Som Pruthi, Chief Medical Officer of enGene Holdings Inc., was granted stock options on July 24, 2024.
• The options are for 110,000 common shares of enGene Holdings Inc.
• The exercise price of the options is $8.65 per share.
• The options vest at 25% on July 24, 2025, and the remaining portion vests monthly over the following three years.
• The options expire on July 24, 2034.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that the company is using standard compensation practices.

Positives

• The granting of stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen also use stock options to align executive incentives with shareholder value.
• The vesting schedule and exercise price are typical for similar grants in comparable companies.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the Chief Medical Officer to drive company success.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates